ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 7.3 | 5.1 | 4.8 |
| Other income | 0.3 | 0.3 | 0.0 |
| Total income | 7.6 | 5.5 | 4.8 |
| Profit before exceptional items & tax | 0.3 | 0.9 | 0.1 |
| Profit before tax | 0.3 | 0.9 | 0.1 |
| Net profit | 0.2 | 0.6 | 0.0 |
| Operating margin | 3.9% | 16.4% | 2.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, quarter on quarter | -66.70% |
|---|---|
| Revenue, year on year | +52.10% |
| Operating profit, year on year | -100.00% |
| Operating profit, quarter on quarter | -100.00% |
BSE results filing, NSE: BERLDRG. Figures extracted from the filing.
Beryl Drugs Ltd: key numbers
- Share price
- ₹26.00
- Market cap
- ₹13.19 Cr
- Revenue (annual)
- ₹18.82 Cr
- Net profit (annual)
- ₹0.42 Cr
- P/E (TTM)
- 21.1×Sector 43.8×
- Promoter holding
- 27.97%+0.15% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Beryl Drugs Ltd
All →Beryl Drugs Board Meeting Date
Beryl Drugs Ltd has notified a board meeting on 14 November 2026 to consider unaudited results for the quarter ended 30 September 2026 and the limited review report. The trading window stays closed until 48 hours after the meeting.
Beryl Drugs Other Announcement
Beryl Drugs Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Beryl Drugs Other Announcement
Beryl Drugs Limited has submitted its quarterly compliance certificates regarding Regulation 74(5) and a non-applicability confirmation for Regulation 57(5) for the quarter ended September 30, 2026.
Beryl Drugs Annual General Meeting
Beryl Drugs Limited held its 33rd Annual General Meeting on September 29, 2026. Shareholders approved audited financial statements, director reappointment, and increased related-party transaction limits.
Beryl Drugs Annual Report
Beryl Drugs Ltd has submitted its 33rd Annual Report for the financial year 2025-26, scheduled for its upcoming Annual General Meeting.
Beryl Drugs Annual General Meeting
Beryl Drugs Ltd has announced the closure of its register of members from September 23 to September 29, 2026, for its 33rd Annual General Meeting.